Alzamend Neuro is trading 7.5% up today at $1.44, extending gains following a $25 million Series D Convertible Preferred Stock agreement with an affiliate of Ault Lending.
- The company has already closed an initial $7.5 million tranche, providing a critical capital injection that addresses previous insolvency concerns.
- Proceeds will support ongoing Phase II clinical trials for AL001, its lead candidate for Alzheimer's and other neurodegenerative diseases.
- Positive sentiment is further bolstered by a broader risk-on market environment as U.S. indices trade higher.